Table 2 Patient and treatment characteristics for the patients with recurrence
From: Assessment and topographic characterization of locoregional recurrences in head and neck tumours
Primary tumour site | Stage | Type RT | Type CH | Dpresc/Gy/#fx | Ddeliv CTV-T/Gy | RT tech | Recurrence location | Diagn./months | Rec vol./cm3 |
|---|---|---|---|---|---|---|---|---|---|
Oral cavity (tongue) | III | Adjuvant (Post-op) | 59.1/30 | 59.0 | 3DCRT | Mobile Tongue + Cervical | 6.7 | 2.0 + 27.6 | |
Oral cavity (mand. gingivae) | IVA | Adjuvant (Post-op) | 59.4/31 | 58.7 | dIMRT | Mandibular gingivae | 7.8 | 7.0 | |
Oral cavity (tongue) | IVA | Adjuvant (Post-op) | 59.0/31 | 59.8 | dIMRT | Cervical | 9.0 | 27.1 | |
Oral cavity (hard palate) | IVA | Concomitant | Cisplatin | 70.2/39 | 70.2 | 3DCRT | Pharynx + Cervical | 8.5 | 16.6 + 82.2 |
Oral cavity (max. gingivae) | IVA | Concomitant (Post-op) | Cisplatin | 64.8/36 | 65.3 | rIMRT | Maxillary gingivae | 8.7 | 9.9 |
Oropharynx (tonsil) | II | Intensive | 70.2/33 | 69.8 | rIMRT | Tonsil | 22.8 | clinical | |
Oropharynx (tonsil) | IVA | Adjuvant (Post-op) | 59.4/33 | 57.0 (pb) | dIMRT | Base tongue | 21.1 | 4.0 | |
Oropharynx (base tongue) | IVA | Sequential | TPF | 69.3/33 | 69.2 | rIMRT | Base tongue | 9.8 | 36.6 |
Oropharynx (base tongue) | IVA | Sequential | TPF | 70.2/39 | 68.1 (pb) | dIMRT | Cervical | 31.2 | 17.1 |
Oropharynx (base tongue) | IVA | Concomitant | Cisplatin | 69.6/33 | 68.7 | IMRT | Tonsil + Cervical + Submandid. | 7.3 | 0.4 + 0.5 + 2.7 |
Hypopharynx (pyriform sinus) | IVA | Concomitant (Post-op) | Cisplatin | 64.8/33 | 56.9/29* | rIMRT | Posterior wall + Cervical | 9.8 | 10.3 + 24.1 |
Hypopharynx (posterior wall) | IVA | Intensive | 69.0/33 | 68.0 | rIMRT | Cervical | 15.4 | 0.6 + 1.0 | |
Hypopharynx (pyriform sinus) | IVA | Sequential | PF | 70.2/39 | 67.7 (pb) | dIMRT | Cervical | 26.7 | 0.3 |
Hypopharynx (pyriform sinus) | IVA | Sequential | PF | 70.2/39 | 70.1 | rIMRT | Pyriform sinus | 9.6 | 8.0 |
Hypopharynx (pyriform sinus) | IVB | Sequential | TPF | 70.2/39 | 72.4 (pb) | dIMRT | Cervical | 23.7 | 15.2 |
Larynx (glottis) | I | Intensive | 66/33 | 65.9 | 3DCRT | Larynx | 12.4 | 14.8 | |
Larynx (glottis) | II | Intensive | 70.0/35 | 69.9 | 3DCRT | Larynx | 9.2 | 19.4 | |
Larynx (supraglottis) | IVA | Concomitant | Cisplatin | 70.2/39 | 69.4 (pb) | dIMRT | Larynx | 32.6 | 1.3 |
Larynx (supraglottis) | IVA | Concomitant (Post-op) | Cisplatin | 64.8/36 | 62.6/35* | dIMRT | Glottis | 8.8 | 1.7 |
Nasopharynx | IIB | Intensive | 70.2/39 | 69.4 | rIMRT | Cervical | 16.0 | 2.7 | |
Nasopharynx | IVB | Concomitant | Cisplatin | 70.2/33 | 75.9 (pb) | IMRT | Right orbit | 34.4 | 11.9 |
Pharyngeal-laryngeal | IVA | Adjuvant (Post-op) | 59.4/33 | 59.7 | dIMRT | Peritracheostomy + Cervical | 25.5 | 0.5 + 44.0 |